ribavirin has been researched along with glycoprotein e2, hepatitis c virus in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 22 (57.89) | 29.6817 |
| 2010's | 13 (34.21) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, GL; González-Peralta, RP; Lau, JY; Liu, WZ; Qian, KP | 1 |
| Alberti, A; Cavalletto, L; Chemello, L; Gerotto, M; Gretch, DR; Polyak, SJ; Pontisso, P; Sullivan, DG | 1 |
| Bruch, K; Kornetzky, I; Kronenberger, B; Lee, JH; Roth, WK; Rüster, B; Sarrazin, C; Zeuzem, S | 1 |
| Changchien, CS; Chen, TM; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lee, JF; Lu, SN; Tung, HD; Wang, JH | 1 |
| Chen, DS; Chen, GH; Kao, JH; Lai, MY; Yang, SS | 1 |
| Chu, CM; Liaw, YF; Sheen, IS | 1 |
| Durantel, D; Khattab, E; Ottevaere, I; Sablon, E; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F | 1 |
| Enomoto, N; Kanazawa, N; Nakagawa, M; Sakamoto, N; Watanabe, H | 1 |
| Hofmann, WP; Sarrazin, C; Zeuzem, S | 1 |
| Gaudy, C; Goudeau, A; Lambelé, M; Lunel, F; Moreau, A; Veillon, P | 1 |
| Alfonso, V; Campos, RH; Mbayed, VA; Sookoian, S | 1 |
| Arataki, K; Chayama, K; Kumada, H; Ohishi, W; Takahashi, S; Tazuma, S; Toyota, K | 1 |
| Burioni, R; Carletti, S; Clementi, M; Craxì, A; Craxì, RD; Mancini, N; Perotti, M; Romanò, L; Zanetti, AR | 1 |
| Bharadwaj, M; Boo, I; Bowden, S; Chin, R; Drummer, H; Fischer, AE; Giourouki, M; Johnson, D; Torresi, J | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; Del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Torres-Puente, M | 1 |
| Bracho, A; Carnicer, F; Castro, JA; Del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Sentandreu, V; Torres-Puente, M | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; Del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Torres-Puente, M; Wrobel, B | 1 |
| Casado, J; Gila, A; León, J; Muñoz de Rueda, P; Palacios, A; Patón, R; Quiles, R; Quintero, D; Ruiz-Extremera, A; Salmerón, J | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Olmo, JD; Ortega, E; Torres-Puente, M | 2 |
| Di Bisceglie, AM; Fan, X; Xu, Y; Xu, Z | 1 |
| Guy, CS; MacParland, SA; Michalak, TI; Pham, TN | 1 |
| Bracho, MA; Cuevas, JM; García-Robles, I; Gonzalez, M; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Torres-Puente, M | 1 |
| Gerner, P; Jenke, AC; Moser, S; Orth, V; Wirth, S; Zilbauer, M | 1 |
| Azevedo, RS; Carrilho, FJ; Gonçalves, L; Malta, Fde M; Medeiros-Filho, JE; Pinho, JR; Silva, LC | 1 |
| Alejska, M; Błażewicz, J; Figlerowicz, M; Formanowicz, P; Jackowiak, P; Kędziora, P; Malinowska, N | 1 |
| Aftab, M; Afzal, S; Akram, M; Awan, Z; Badar, S; Fatima, Z; Hussain, A; Idrees, M; Khubaib, B | 1 |
| Aftab, M; Afzal, S; Akram, M; Badar, S; Hussain, A; Idrees, M; Ilyas, M; Khubaib, B; Zafar, S | 1 |
| Jabbari, H; Malboobi, MA; Merat, S; Mousavi-Fard, SH; Sabahi, F; Shahzamani, K; Sharifi, H; Yahoo, N | 1 |
| Berak, H; Cortés, KC; Fic, M; Horban, A; Ośko, I; Pawełczyk, A; Radkowski, M | 1 |
| Bolcic, F; Laufer, N; Moretti, F; Quarleri, J; Sede, M; Vazquez, M; Westergaard, G | 1 |
| Bolcic, F; Cassino, L; Laufer, N; Quarleri, J; Reynoso, R; Torres, C | 1 |
| Dou, XG; Han, F; Zhang, D; Zhang, L | 1 |
| Baumert, TF; Doffoël, M; Donlin, MJ; Erba, AC; Fafi-Kremer, S; Fofana, I; Gut, JP; Habersetzer, F; Moenne-Loccoz, R; Murray, JM; Schvoerer, E; Stoll-Keller, F; Tavis, JE; Turek, M; Velay, A; Zeisel, MB | 1 |
| Bukh, J; Carlsen, TH; Christensen, PB; Jensen, TB; Krarup, H; Laursen, AL; Pedersen, J; Schønning, K; Weis, N | 1 |
| Baumert, TF; Doffoël, M; Fofana, I; Gut, JP; Habersetzer, F; Moenne-Loccoz, R; Murray, JM; Schvoerer, E; Stoll-Keller, F; Velay, A; Zeisel, MB | 1 |
| Berak, H; Bukowska-Ośko, I; Cortés, KC; Horban, A; Laskus, T; Maroszek, K; Pawełczyk, A; Perlejewski, K; Płoski, R; Radkowski, M; Zagordi, O | 1 |
| Geller, J; Jakovleva, J; Kurtenkov, O; Sergejev, B | 1 |
2 review(s) available for ribavirin and glycoprotein e2, hepatitis c virus
| Article | Year |
|---|---|
[Virus factors determining the outcome of IFN treatment for chronic hepatitis C].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins; Viral Proteins | 2004 |
Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Humans; Interferon-alpha; Mutation; Ribavirin; Viral Envelope Proteins; Viral Nonstructural Proteins | 2005 |
3 trial(s) available for ribavirin and glycoprotein e2, hepatitis c virus
| Article | Year |
|---|---|
Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Follow-Up Studies; Genetic Heterogeneity; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Viral Envelope Proteins | 1997 |
Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutation; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins | 2005 |
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Topics: 5' Untranslated Regions; Adult; Antibody Specificity; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Epitopes; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Neutralization Tests; Polyethylene Glycols; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Envelope Proteins; Viremia | 2006 |
33 other study(ies) available for ribavirin and glycoprotein e2, hepatitis c virus
| Article | Year |
|---|---|
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins | 1999 |
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Molecular Sequence Data; Mutation; Phylogeny; Ribavirin; Viral Envelope Proteins; Viral Nonstructural Proteins | 2000 |
Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Eukaryotic Initiation Factor-2; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Alignment; Viral Envelope Proteins; Viral Nonstructural Proteins | 2003 |
Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; eIF-2 Kinase; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Phosphorylation; Point Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2003 |
Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins | 2004 |
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Capsid Proteins; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins | 2004 |
Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Phylogeny; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2005 |
Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Topics: 5' Untranslated Regions; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Genetic Drift; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mutation; Phylogeny; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins; Viral Nonstructural Proteins | 2006 |
Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Neutralization Tests; Polyethylene Glycols; Polymorphism, Single-Stranded Conformational; Ribavirin; Viral Envelope Proteins | 2007 |
Contribution of insertions and deletions to the variability of hepatitis C virus populations.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Gene Deletion; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutagenesis, Insertional; Ribavirin; Sequence Alignment; Spain; Species Specificity; Viral Envelope Proteins; Viral Nonstructural Proteins | 2007 |
Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Genetic variability in hepatitis C virus and its role in antiviral treatment response.
Topics: Amino Acid Substitution; Antiviral Agents; Conserved Sequence; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutation, Missense; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Topics: Adult; Age Factors; Alanine Transaminase; Base Sequence; Cluster Analysis; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Odds Ratio; Phylogeny; Prospective Studies; Protein Structure, Tertiary; Ribavirin; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation, Missense; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.
Topics: Amino Acid Sequence; Antiviral Agents; Genome, Viral; Hepacivirus; Humans; Models, Genetic; Molecular Sequence Data; Mutation; Phylogeny; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Sequence Homology, Amino Acid; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antiviral Agents; Cells, Cultured; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Ribavirin; RNA, Viral; T-Lymphocytes; Tetraspanin 28; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mutation; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
The role of positive selection in hepatitis C virus.
Topics: Amino Acid Sequence; Chi-Square Distribution; Cohort Studies; Complementarity Determining Regions; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Selection, Genetic; Sequence Analysis, Protein; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy.
Topics: Adolescent; Amino Acid Sequence; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult | 2009 |
Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Molecular Sequence Data; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins | 2010 |
Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
Topics: Adolescent; Antiviral Agents; Child; Cluster Analysis; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins | 2010 |
Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Eukaryotic Initiation Factor-2; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Pakistan; Protein Structure, Tertiary; Ribavirin; Sequence Alignment; Viral Envelope Proteins | 2010 |
Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
Topics: Amino Acid Substitution; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Load | 2011 |
Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2011 |
[Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Poland; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Ribavirin; Sequence Alignment; Viral Envelope Proteins | 2011 |
Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Conserved Sequence; eIF-2 Kinase; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Phosphorylation; Phylogeny; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Serum; Viral Envelope Proteins | 2012 |
Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Topics: 5' Untranslated Regions; Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins | 2012 |
Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult | 2012 |
Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Topics: Adult; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Computational Biology; Female; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Immune Evasion; Male; Middle Aged; Mutagenesis, Site-Directed; Mutation; Neutralization Tests; Ribavirin; Structure-Activity Relationship; Treatment Failure; Viral Envelope Proteins; Virus Internalization | 2013 |
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Topics: Antibodies, Neutralizing; Culture Techniques; DNA, Recombinant; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mutation; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2013 |
Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Models, Biological; Models, Statistical; Multivariate Analysis; Phylogeny; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2013 |
Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
Topics: Adult; Antiviral Agents; Base Sequence; Female; Genetic Heterogeneity; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2014 |
Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Genotype; Glycosylation; Hepacivirus; Hepatitis C; Humans; Immunoglobulin G; Interferon alpha-2; Liver Cirrhosis; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Young Adult | 2020 |